



# EUROPEAN UNION (EU) PRESIDENCY EVENT

## European Alliance for Personalised Medicine Congress

### Personalising Your Health: A Global Imperative!

27 November 2017

10:00 - 10:30	Press Conference
10.30 - 11.15	<p><b>Opening of EAPM Congress</b></p> <p><b>Chair: Denis Horgan</b> <i>Executive Director, European Alliance for Personalised Medicine (EAPM) Brussels, Belgium</i></p> <p><b>Welcome: David Byrne</b> <i>Former European Commissioner for Health and Consumer Protection and Co-Chair EAPM, Brussels, Belgium</i></p> <p><b>Mark Lawler</b> <i>Chair in Translational Cancer Genomics, Queen's University Belfast, UK</i></p> <p><b>Kersti Kaljulaid</b> <i>President of Estonia (TBC)</i></p> <p><b>Simon Harris</b> <i>Minister of Health, Republic of Ireland (TBC)</i></p> <p><b>Lydia Mutsch</b> <i>Minister of Health, Luxembourg (TBC)</i></p> <p><i>Minister of Health, Northern Ireland (TBC)</i></p>
11.15 - 13:00	<p><b>Opening Plenary Presidential Session: Round Table "Growth in Personalised Healthcare - The promise for future generations"</b></p> <p><b>Chair: Gordon McVie</b> <i>Co-Chair EAPM, Brussels, Belgium</i></p> <p><b>Carlos Moedas</b> <i>Commissioner, DG Research, Science and Innovation, Brussels, Belgium (TBC)</i></p> <p><b>Desmond Schatz</b> <i>Associate Chairman of Pediatrics, School of Medicine University of Florida, Gainesville, Florida USA</i></p> <p><b>Mary Baker</b> <i>Former President European Brain Council, Brussels, Belgium</i></p> <p><b>Denis Lacombe</b> <i>Director General, European Organisation for Research and Treatment of Cancer, Brussels, Belgium</i></p> <p><b>Chris Round</b> <i>Head of EMEA Region for Biopharma Global Commercial Operations, Merck, London, UK</i></p> <p><b>Lorraine Nolan</b> <i>Chief Executive, Health Products Regulatory Authority, Dublin, Ireland</i></p>

13.00 - 13:45	Lunch and Networking				
13.45- 15.30	Parallel Sessions				
<p><b>Centre for Cancer Research and Cell Biology 10 Year Anniversary Symposium</b></p>	<p><b>The Value of Sustainable Healthcare</b></p>	<p><b>European Hematology Association Session – Personalising treatment of blood diseases – Taking advantage of the leukemia/lymphoma genome</b></p>	<p><b>Capturing the Global Picture in Precision Medicine</b></p>	<p><b>A Tale of Two Cities: a whole system approach to personalised medicine and health</b></p>	
<p><b>Chair: David Waugh</b> <i>Director, Centre for Cancer Research and Cell Biology, Belfast, UK</i></p>	<p><b>Co-Chair: Denis Horgan</b> <i>Executive Director, European Alliance for Personalised Medicine, Brussels, Belgium</i></p> <p><b>Co-Chair: Stephane Hogan</b> <i>Head of Sector for Neurosciences DG Research &amp; Innovation, Brussels, Belgium (TBC)</i></p>	<p><b>Chair: Ulrich Jäger</b> <i>Professor of Hematology, Medical University of Vienna, Austria</i></p>	<p><b>Chair: Richard Barker</b> <i>Center for the Advancement of Sustainable Medical Innovation (CASMI), Oxford/University College London, UK</i></p> <p><b>Co-Chair: Mark Lawler</b> <i>Centre for Cancer Research and Cell Biology, Queen's University Belfast, UK</i></p>	<p><b>Chair: Gianni D'Errico</b> <i>European Funding Officer, Regional Foundation for the Biomedical Research, Lombardy, Milan, Italy</i></p> <p><b>Co-Chair: Michael Paul Messenger</b> <i>Principal Healthcare Scientist, Leeds Institute of Cancer &amp; Pathology, Leeds, UK</i></p>	
<p><b>Owen Sansom</b> <i>Deputy Director, Cancer Research UK Beatson Institute, Glasgow, UK</i></p> <p><b>Denis Lacombe</b> <i>Director General, European Organisation for Research and Treatment of Cancer, Brussels, Belgium</i></p>	<p><b>Giovanni Esposito</b> <i>European Brain Council, Brussels, Belgium</i></p> <p><b>Michela Tinelli</b> <i>Department of Social Policy, London School of Economics, London, United Kingdom</i></p> <p><b>Patrice Boyer</b> <i>President, European Psychiatric Association, Paris, France</i></p> <p><b>Maarten IJzerman</b> <i>Chair Department of Health Technology &amp; Services Research, University of Twente, Netherlands</i></p>	<p><b>"Personalisation in hematology"</b> <b>Ulrich Jäger</b> <i>Professor of Hematology, Medical University of Vienna, Austria</i></p> <p><b>"The hematology research roadmap"</b> <b>Christine Chomienne</b> <i>Institut National du Cancer, Paris France</i></p> <p><b>The HARMONY project</b></p> <p><b>Speaker to be confirmed</b></p> <p><b>Magda Chlebus</b> <i>Director Science Policy, EFPIA. Brussels, Belgium (TBC)</i></p>	<p><b>Vineet Datta</b> <i>Executive Director, Datar Genetics Limited, New Delhi, India</i></p> <p><b>Speakers to be confirmed</b></p>	<p><b>"PPM+The Leeds Care Record: Big Data supporting PM"</b> <b>Geoff Hall</b> <i>Chief Clinical Information Officer, Leeds Teaching Hospital NHS Trust, Leeds, UK (TBC)</i></p> <p><b>"Early Health Economic Modelling – developing the evidence of value"</b> <b>Bethany Shinkins</b> <i>Test Evaluation Group Lead, University of Leeds, Leeds, UK (TBC)</i></p> <p><b>"Overview of the management of people affected by chronic disease"</b> <b>Paolo Mocarelli</b> <i>Scientific Director of "don Gnocchi Foundation", Milan, Italy (TBC)</i></p> <p><b>"Prevention of Chronic diseases and benefits for the healthcare systems"</b> <b>Sergio Abrignani</b> <i>Scientific Director Istituto Nazionale di Genetica Molecolare, Milano, Italy (TBC)</i></p>	

	<p><b>Torsten Haferlach</b> CEO, Munich Leukemia Laboratory, Munich, Germany</p>	<p><b>"Access to Innovative Medicines"</b> <b>Anton Hagenbeek</b> University of Amsterdam - Academic Medical Centre, The Netherlands</p>		<p><b>"Public Consultation on PM in Lombardy Regions - Overviews and scientific, industrial and policy outcomes"</b> <b>Luca del Gobbo</b> Regional Ministry University, Research and Open Innovation, Milan, Italy</p> <p><b>"Accelerating PM and Health - a whole system approach"</b> <b>Michael Paul Messenger</b> Principal Healthcare Scientist, Leeds Institute of Cancer &amp; Pathology, Leeds, UK</p>
	<p><b>Anita MacDonald</b> Consultant Dietician, Inherited Metabolic Disorder, Birmingham Children's Hospital, United Kingdom</p>			

<p><b>15.30 - 17.00</b></p>	<p><b>Presidential Session - Shaping Future Healthcare and the One Health Agenda I</b></p> <p><b>Co-Chair: Alastair Kent</b> <i>Director, Genetic Alliance, UK</i></p> <p><b>Sue Hill, OBE</b> <i>Chief Scientific Officer, NHS England, UK</i></p> <p><b>Sir John Chisholm</b> <i>Executive Chair, Genomics England, UK</i></p> <p><b>Mark Caulfield</b> <i>Chief Scientist, Genomics England, Cambridge, UK</i></p> <p><b>Ian Young</b> <i>Chief Scientific Advisor, Department of Health, Social Services and Public Safety, Belfast, Northern Ireland</i></p> <p><b>Kim Stratton</b> <i>Head International Commercial, Shire Pharmaceuticals (TBC)</i></p>
-----------------------------	--

<p><b>17.00 - 17:15</b></p>	<p><b>Coffee, Posters and Networking</b></p>
-----------------------------	--

<p><b>17.15 - 19.00</b></p>	<p><b>Presidential Session - Shaping Future Healthcare and the One Health Agenda II</b></p> <p><b>Chair: Peter Honggaard Anderson</b> <i>Innovation Fund, Denmark</i></p> <p><b>Atul Gawande</b> <i>Professor of Health Policy and Management, Harvard T.H. Chan School of Public Health, Boston, USA</i></p> <p><b>Richard Barker, OBE</b> <i>Center for the Advancement of Sustainable Medical Innovation (CASMI), University of Oxford/University College London, UK</i></p> <p><b>Koen Kas</b> <i>Professor of Biochemistry, University of Gent, Belgium</i></p>
-----------------------------	--

19.00- 20.00	<b>Special lecture</b> <b>Alexander Eggermont</b> <i>Director General, Institute Gustave Roussy, Paris, France</i>
20:30 – 22:00	<b>Welcome Reception, Belfast City Hall (hosted by Lord Mayor)</b>  <b>Mike Thompson</b> <i>Chief Executive Officer, Association of British Pharmaceutical Industries, UK</i>  <b>Kersti Kaljulaid</b> <i>President, Estonia (TBC)</i>

## 28 November 2017

07:30 – 08:15	<b>Highlights of the Day and Press Briefing</b>				
07:30 – 08:30	<b>Meet the Policy Maker</b>	<b>Meet the Professor</b>	<b>Meet the Professor/ Business Leader</b>	<b>Meet the Patent Advocate</b>	<b>Meet the Professor/ Business Leader</b>
08:30 – 10:00	<b>Presidential Session: Big Data Saves Lives</b>  <b>Co-Chair: Mark Lawler</b> <i>Chair in Translational Cancer Genomics, Queen's University Belfast, UK and Co-Chair Clinical Cancer Genome Task Team, Global Alliance for Genomics and Health (GA4GH)</i>  <b>Co-Chair: Julie Wilson</b> <i>Associate Director, Wellcome Trust Sanger Centre Cambridge UK and Global Alliance for Genomics and Health (GA4GH)</i>  <b>Ewan Birney</b> <i>Director European Bioinformatics Institute, Cambridge UK and Chair Global Alliance for Genomics and Health</i>  <b>Andrew Morris</b> <i>Director Health Data Research UK</i>  <b>Margaret Grayson</b> <i>Chair Northern Ireland Cancer Research Consumer Forum, Belfast, UK</i>  <b>Ain Aaviksoo</b> <i>Deputy Secretary General for E-services and Innovation, Ministry of Social Affairs, Estonia</i>  <b>Ernst Hafen</b> <i>Institute of Molecular Systems Biology, ETH Zurich, Switzerland</i>				
10:00 – 10:30	<b>Coffee, Posters and Networking</b>				
10:00 – 10:30	<b>Speed Networking</b>				
10:00 – 10:30	<b>Meet the Cancer Patient</b>	<b>Meet the Diabetes Patient</b>	<b>Meet the Patient (Brain Diseases)</b>	<b>Meet the Patient with co-morbidities</b>	<b>Meet the Rare Disease Patient</b>



<p><b>Capturing the training need for Personalised Medicine</b></p>	<p><b>Ulster University Session on Precision Medicine in Multi-morbid Inflammatory Disease</b></p>	<p><b>Centre for Experimental Medicine (CEM) Queen's University Belfast Special Session: Eyes do not lie – you are what you can see! Options for personalised medicine in eye diseases</b></p>	<p><b>European Bioinformatics Institute-Global Alliance for Genomics and Health (GA4GH) Special Session Empowering personalised health through data sharing</b></p>	<p><b>Converting Hospitals to a Personalised Health Agenda</b></p>
<p><b>"Manufacturing processes of the future"</b> <b>John Milne</b> <i>Training Director, National Institute for Bioprocessing Research and Training (NIBRT), Dublin, Ireland</i></p>	<p><b>Chair: Tony Bjourson</b> <i>Director, Northern Ireland Centre for Stratified Medicine, Biomedical Sciences Research Institute, Ulster University, Derry, UK</i></p> <p><b>"Stratified Medicine in Proinflammatory Multi-morbid Disease"</b> <b>Tony Bjourson</b> <i>Director, Northern Ireland Centre for Stratified Medicine, Biomedical Sciences Research Institute, Ulster University, Derry, UK</i></p>	<p><b>Chair: Tunde Peto</b> <i>Centre for Experimental Medicine, Queen's University Belfast, UK</i></p> <p><b>"Pharmacogenetics and the individual patient: the industry perspective"</b> <b>Everson Nogoceke</b> <i>Biomarker Experimental Medicine Leader, Roche Pharma Research &amp; Early Development, Roche, Basel, Switzerland</i></p>	<p><b>Chair: Serena Scollen</b> <i>Head of Human Genomics and Translational Data, Elixir, Cambridge, UK</i></p> <p><b>Julie Wilson</b> <i>Associate Director, Wellcome Trust Sanger Centre, Cambridge, UK; Clinical Working Group, Global Alliance for Genomics and Health (GA4GH)</i></p>	<p><b>Chair: Pascal Garel</b> <i>Chief Executive, Hospital and Healthcare Federation (HOPE), Brussels, Belgium</i></p> <p><b>Regional Level</b> <b>Eva Weinreich-Jensen</b> <i>Vice-President, HOPE &amp; Senior Advisor, Danish Regions, Denmark</i></p>
<p><b>"The future workforce"</b> <b>Killian O'Driscoll</b> <i>Director of Projects at NIBRT, Dublin, Ireland</i></p>	<p><b>"A Gut Feeling about Mental Health: Precision Medicine and the Microbiome"</b> <b>John F. Cryan</b> <i>Chair, Department of Anatomy and Neuroscience, Principal Investigator APC Microbiome Institute, University College Cork, Ireland</i></p>	<p><b>"Precision Ophthalmology: Lessons from age related macular disease"</b> <b>Carel Hoyng</b> <i>Professor of Ophthalmology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands</i></p>	<p><b>Serena Scollen</b> <i>Head of Human Genomics and Translational Data, Elixir, Cambridge, UK</i></p>	<p><b>Dr Bernard Maillet</b> <i>Vice-President and Chair of the eHealth working group, Standing Committee of European Doctors - CPME</i></p>
<p><b>Facility of the future – Personalised Medicine Group (name TBC)</b></p>	<p><b>"Personalised Medicine approaches to immunological mechanism and treatment for major psychiatric disorders"</b> <b>Golam Khandaker</b> <i>Wellcome Trust Intermediate Clinical Fellow, Department of Psychiatry, University of Cambridge, UK</i></p>	<p><b>"The myopia epidemic: can we individualise the message?"</b> <b>Caroline Klaver</b> <i>Professor of Ophthalmology at Erasmus MC &amp; Radboud UMC The Netherlands</i></p>	<p><b>Thomas Keane</b> <i>Team Leader: EGA, EVA and archive infrastructure EMBL-EBI</i></p>	<p><b>"From Carpet Bombing to Sniper Fire: Genomics to Precision Cancer Care in Children and Adolescents"</b> <b>Owen Smith CBE</b> <i>Professor of Paediatric and Adolescent Medicine, University College Dublin and Director, Clinical Academic Directorate for Cancer Care, Ireland East Hospital Group Ireland</i></p>

<p><b>Manufacturing 4.0 – Siemens (name TBC)</b></p>		<p><b>“Micronutrients and age related eye disease: from diet through drugs to prevention of blindness”</b>  <b>Imre Lengyel</b>  <i>Centre for Experimental Medicine, Queen’s University Belfast, UK</i></p> <p><b>“Curing diabetic eye disease? - from the bench to treating patients as individuals”</b>  <b>Alan Stitt</b>  <i>Professor, Centre for Experimental Medicine, Queen’s University Belfast, UK</i></p> <p><b>“How to improve imaging technology to accommodate individual needs?”</b>  <b>Anne-Marie Cairns,</b>  <i>Global Vice President of Clinical &amp; Medical Affairs, Optos, Halbeath, UK</i></p>	<p><b>Torsten Schwede</b>  <i>Professor of Bioinformatics, Swiss Institute of Bioinformatics, University of Basel, Switzerland</i></p> <p><b>Sarion Bowers, Policy Lead</b>  <i>Sanger Institute</i></p> <p><b>Jeff Barrett, Director,</b>  <i>Centre for Therapeutic Target Validation, Cambridge, UK</i></p>	<p><b>Manuel Salto-Tellez</b>  <i>Professor of Pathology, Centre for Cancer Research and Cell Biology, Queen’s University Belfast, UK</i></p> <p><b>Stephen McMahon</b>  <i>Chairman and co-founder of the Irish Patients’ Association (IPA), Dublin, Ireland</i></p>
--	--	--	--	---

12:00 - 12.30	Proffered Paper Presentations	Proffered Paper Presentations	Proffered Paper Presentations	Proffered Paper Presentations	Proffered Paper Presentations
---------------	-------------------------------	-------------------------------	-------------------------------	-------------------------------	-------------------------------

12:30 – 13:30	<b>Lunch, Posters and Networking</b>				
---------------	--------------------------------------	--	--	--	--

13:00 – 14:30	<p><b>Presidential Session: Research Frontiers in Personalised Medicine</b></p> <p><b>Co-Chair: Mairead O’Driscoll</b>  <i>Health Research Board of Ireland, Dublin, Ireland and IC-Per Med</i></p> <p><b>Co-Chair: Denis Horgan</b>  <i>Executive Director, European Alliance for Personalised Medicine (EAPM) Brussels, Belgium</i></p> <p><b>Sir Harpal Kumar</b>  <i>Chief Executive Officer, Cancer Research UK</i></p> <p><b>Holger Hess-Stumpp</b>  <i>Director, Global External Innovation &amp; Alliance, Oncology, Bayer Healthcare, Leverkusen, Germany (TBC)</i></p> <p><b>William Pao</b>  <i>Global Head, Oncology Discovery &amp; Translational Area (pRED), Roche, Basel, Switzerland (TBC)</i></p> <p><b>Alberto Bardelli</b>  <i>President Elect, European Association for Cancer Research, Torino, Italy</i></p> <p><b>Wolf-Dieter Ludwig</b>  <i>CPME representative on the European Medicines Agency Management Board, Berlin, Germany</i></p>				
---------------	---	--	--	--	--

14:30 – 15:00	<b>Coffee, Posters and Networking</b>				
---------------	---------------------------------------	--	--	--	--

<b>Speed Networking</b>					
14:30 – 15:00	Lydia Makaroff Director, ECPC	Meet the Diabetes Patient	Meet the Patient (Brain Diseases)	Meet the Patient with co-morbidities	Meet the Rare Disease Patient

Mini Symposium: Breast Cancer: Dealing with Complexity Head on to Better Personalised Treatment	Genomics and Medicine – Crossing the Rubicon	Realising precious therapeutics in neurological disease	Innovation, Screening, Guidelines: The Case of Lung Cancer	Special Symposium: Implementing existing knowledge and innovation – a European Perspective
<p><b>Chair: William Gallagher</b> Director Conway Institute for Biomolecular Research, University College Dublin, Ireland</p>	<p><b>Chair: Shane McKee</b> Director Northern Ireland Genomics Medicine Centre, Belfast, UK</p>	<p><b>Chair: Gianpiero Cavalleri</b> Associate Professor in Human Genetics Royal College of Surgeons in Ireland, Dublin, Ireland</p>	<p><b>John Field</b> Professor of Molecular Oncology, University of Liverpool, UK</p>	<p><b>Chair: Marius Gaenta</b> Co-Founder, Center for Innovation in Medicine, Bucharest, Romania</p>
<p><b>Michael J. Duffy</b> Adjunct Professor, School of Medicine and Medical Science, University College Dublin, Ireland</p>	<p><b>Sir John Burn</b> Professor of Clinical Genetics University of Newcastle, UK</p>	<p><b>Slave Petrovski</b> NHMRC Fellow, Royal Melbourne Hospital, University of Melbourne, Australia</p>	<p><b>Giulia Veronesi</b> Humanitas Research Hospital, Milan, Italy</p>	<p><b>Francoise Meunier</b> Vice-President, Federation of European Academies of Medicine, Brussels, Belgium</p>
<p><b>Ivana Sestak</b> Lecturer in Medical Statistics, Wolfson Institute of Preventive Medicine, Queen Mary University of London, UK</p>	<p><b>Sally John</b> VP Genomics and Computational Biology, Biogen, Cambridge, USA (TBC)</p>	<p><b>"eHealth": Mary Fitzsimons</b> Medical Physicist, Beaumont Hospital, Dublin, Ireland</p>	<p><b>Antoni Montserrat</b> Senior Expert on Cancer and Rare Diseases, DG Public Health, European Commission, Brussels, Belgium</p>	<p><b>Arnie Purushotham</b> Director of King's Health Partners Cancer Centre (KHPCC), Chair of Breast Cancer at King's College London (KCL) Trust (TBC)</p>
<p><b>Martine Piccart</b> Professor of Oncology, Université Libre de Bruxelles; Director of Medicine, Jules Bordet Institute, Brussels, Belgium</p>	<p><b>Nadeem Sarwar</b> President, Eisai AiM Institute, Boston USA (TBC)</p>	<p><b>"Clinical integration" Norman Delanty</b> Professor of Clinical Neurological Sciences, Beaumont Hospital, Dublin, Ireland</p>	<p><b>Stefania Vallone</b> LuCE (Lung Cancer Europe), Bern, Switzerland</p>	<p><b>Florin Buicu</b> President Health Commission, Chamber of Deputies, Romanian Parliament</p>
<p><b>Fergus Couch</b> Chair, Division of Experimental Pathology, Mayo Clinic, Rochester, Minnesota, USA</p>	<p><b>"Involving the public in conversations about Genomics: making Personalised Medicine resonate" Anna Middleton</b> Head of Society and Ethics Research Wellcome Genome Campus, Cambridge, UK</p>		<p><b>Mina Gaga</b> President Elect, European Respiratory Society, Athens, Greece</p>	<p><b>Beata Jagielska</b> Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology; Department of Oncological Diagnostic, Cardio-Oncology and Palliative Care, Warsaw, Poland</p>
<p><b>Alric Rüther</b> Head, Department of Health Care Quality, International Affairs, Institute for Quality and Efficiency in Health Care (IQWiG), Cologne, Germany (TBC)</p>			<p><b>Oudkerk Matthijs</b> Scientific Director Centre for Medical Imaging – North East Netherlands; Principal investigator NELSON STUDY: Dutch-Belgian study on lung cancer screening</p>	

16:30 - 17:30	Proffered Paper Presentations	Proffered Paper Presentations	Proffered Paper Presentations	Proffered Paper Presentations	Proffered Paper Presentations
17:00 - 17:30	Coffee, Posters and Networking				
17:30 - 19:00	Parallel Sessions				
	<b>Cancer in Eastern Europe: Responding to the Challenge</b>  <b>Co-Chair: Mark Lawler</b> <i>Centre for Cancer Research and Cell Biology, Queen's University Belfast, UK</i>  <b>Speakers to be confirmed</b>	<b>HARMONY Session</b>  <b>Chair: Carin Smand</b> <i>Managing Director, EHA (TBC)</i>  <b>Fionnuala Doyle</b> <i>VP &amp; Global Head Policy of Oncology, Novartis, New York, US</i>	<b>Clinical Innovation Showcase: 'Northern Ireland Clinical Research Network(NICRN) : supporting clinical research in personalised medicine'</b>  <b>Co-Chairs:</b> <b>Paul Biagioni, Maurice O'Kane</b> <i>NICRN</i>  <b>"Introduction"</b> <b>Maurice O'Kane</b> <i>NICRN</i>  <b>"Cardiovascular Disease"(Exact title TBC)</b> <b>Patrick Donnelly</b> <i>Co-clinical Lead of the Northern Ireland Cardiovascular Research Network, South Eastern Health and Social Care Trust, UK</i>  <b>"Diabetes" (Exact title TBC)</b> <b>Vivien Coates</b> <i>Professor of Nursing Research, Ulster University, Coleraine, UK</i>  <b>"Renal disease" (Exact title TBC)</b> <b>Peter Maxwell</b> <i>Professor of Renal Medicine, Queen's University Belfast, UK</i>  <b>Neil Morgan</b> <i>Consultant Nephrologist, Newry, UK</i>	<b>Personalised Health and rare disease</b>  <b>Chair: Alastair Kent</b> <i>Chair Rare Disease UK; Director, Genetic Alliance UK</i>  <b>Yann Le Cam</b> <i>Chief Executive Officer of EURORDIS-Rare Diseases Europe (TBC)</i>  <b>Anders Olauson</b> <i>Chair, NGO Committee for Rare Diseases, United Nations, New York</i>  <b>Maria Luisa Silva</b> <i>Director of United Nations Development Program (UNDP) Office in Geneva, Switzerland (TBC)</i>  <b>Ana Rath</b> <i>Director, Orphanet, Paris, France</i>	
19:00 - 20:00	<b>Patrick Johnston Memorial Lecture</b> <b>Paul Workman</b> , <i>Chief Executive and President, The Institute of Cancer Research (ICR) UK (TBC)</i>				
19:00 - 20:00	Poster Session				
20:30 - 22:30	<b>Gala Dinner Titanic Belfast</b>  <b>Taavi Rõivas</b> <i>former leader of the Reform Party and former Prime Minister of Estonia</i>				





<b>07:30 - 08:00</b>	<b>Highlights of the Day and Press Briefing</b>				
<b>07:30 - 08:30</b>	<b>Meet the Policy Makers</b>	<b>Meet the Professor/ Business Leader</b>	<b>Meet the Professor/ Business Leader</b>	<b>Meet the Policy Makers</b>	<b>Meet the Professor/ Business Leader</b>
<b>08:00 - 09:30</b>	<p><b>Presidential Session: Is precision medicine the route to a healthy world?</b></p> <p><b>Chair: John Bowis</b> <i>Former Minister for Health UK and Former MEP</i></p> <p><b>Speaker to be confirmed</b></p> <p><b>Vytenis Andriukaitis</b> <i>European Commissioner for Health and Food Safety, Brussels, Belgium (TBC)</i></p> <p><b>Ian Banks</b> <i>President, European Men's Health Forum</i></p> <p><b>Tom Lillie</b> <i>Vice President, Head of European Clinical Development MSD, London, UK</i></p>				
<b>09:30 - 10:00</b>	<b>Coffee, Posters and Networking</b>				
<b>10:00 - 11:30</b>	<b>Parallel Sessions</b>				
	<b>Personal Oncology Approaches - reflections from both sides of the pond</b>	<b>The 'molecularly unstratified' patient: a focus for moral, psycho-social and societal research</b>	<b>Regulation of diagnostic tests used in personalised medicine</b>	<b>Immunotherapy: The next Big Thing?</b>	<b>Preserving Health – what can we do at European Level?</b>
	<p><b>Chair: Etienne Richter</b> <i>Associate Director, CIHR Institute of Genetics, Montreal, Canada</i></p> <p><b>Fabien Calvo</b> <i>Scientific Director, Cancer Core Europe, Paris, France</i></p> <p><b>“Biomarkers for Pediatric Glioblastoma through Genomics and Epigenomics”</b> <b>Nada Jabado</b> <i>Associate Professor of Pediatrics, McGill University Health Centre, Montreal, Canada</i></p>	<p><b>Chair: Deborah Alsina</b> <i>Chief Executive MBE, Bowel Cancer UK</i></p> <p><b>Tim Maughan</b> <i>Professor of Clinical Oncology, University of Oxford; MRC/CRUK Stratification in Colorectal Cancer Consortium</i></p> <p><b>Joshua Hordern</b> <i>Associate Professor of Christian Ethics, University of Oxford; Oxford Healthcare Values Partnership, University of Oxford</i></p>	<p><b>Chair: Jonathan Truelove</b> <i>Vice President, General Counsel – International, Genomic Health, Geneva, Switzerland</i></p> <p><b>Sheila Walcott</b> <i>Founder and CEO, Goldbug Strategies, Washington, USA</i></p> <p><b>Stephen Lee</b> <i>Biosciences Team Manager, Medicines and Healthcare products Regulatory Agency, London, UK (TBC)</i></p>	<p><b>Chair: Gennaro Ciliberto</b> <i>Scientific Director, IRCCS, Istituto Nazionale Tumori “Regina Elena, Rome, Italy</i></p> <p><b>“Immunophenotypes and antigenomes of solid cancers”</b> <b>Zlatko Trajanoski</b> <i>Director, Division for Bioinformatics, Biocenter, Innsbruck Medical University (TBC)</i></p> <p><b>“Clonal neoantigens and sensitivity to immune checkpoint blockade”</b> <b>Sergio Quezada</b> <i>Professional Research Fellow, Research Department of Hematology, UCL Cancer Institute (TBC)</i></p>	<p><b>Chair: Tit Albreht</b> <i>Institute of Public Health, Slovenia</i></p> <p><b>Sebastian Schmidt</b> <i>Head of Strategy and Medical Affairs Computed Tomography at Siemens Healthineers</i></p> <p><b>“Public health genomics”</b> <b>Marc Van den Bulcke</b> <i>Head Cancer Centre, OD Public Health and Surveillance Scientific Institute of Public Health, Belgium</i></p>

**“Personalized Cancer Immunotherapy”**

**Denis Claude Roy**  
Director Cellular Therap Laboratory, Scientific Director, Centre de recherche, Hospital Maisonneuve-Rosemont, Montreal, Canada

**“Personalized Oncogenomics (POG), The BC Cancer Agency’s Personalized Oncogenomics Program”**

**Marco Marra**  
Director and Distinguished Scientist, Canada’s Michael Smith Genome Sciences Centre, BC Cancer Agency, Vancouver, Canada

**Richard Sullivan**

Chair in Cancer Policy and Global Health, Kings College London

**Alison Hall**

Head of Humanities, PHG Foundation, Cambridge, UK

**Liz Morrell**

Postdoctoral researcher, Centre for the Advancement of Sustainable Medical Innovation (CASMI), Radcliffe Department of Medicine, University of Oxford, UK

**Rob Horne**

Professor of Behavioural Medicine, UCL School of Pharmacy; Centre for the Advancement of Sustainable Medical Innovation, London, UK

**Alastair Kent**

Chair Rare Disease UK; Director, Genetic Alliance UK

**Sue Spencer**

Head of Global Medical Device Services, UL, UK (TBC)

**Dr Panos Kanavos**

Reader in International Health Policy, Department of Social Policy, London School of Economics, London, UK

**British Standards Institution representative**

**Speaker to be confirmed**

**“Development of neoantigen-based cancer”**

**Ugur Sahin**  
co-founder and CEO of BioNTech AG, Mainz, Germany (TBC)

**“Design and testing of novel concepts for adoptive immunotherapy of cancer”**

**Ton Schumacher**  
Group Leader, Immunology, Netherlands Cancer Institute (TBC)

**Stephan Scherer**

VP Global Head Correlative Science, Novartis (TBC)

**“Cancer screening”**

**Ahti Anttila**  
Research Director of the Mass Screening Registry of the Finnish Cancer Registry (TBC)

**Michel Coleman**

Professor of Epidemiology and Vital Statistics, Department of Non-Communicable Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, UK

**“Survivorship issues”**

**Dr Claudia Ferrari**  
Department of Training and Demography for Health Professionals, The French National Cancer Institute (TBC)

11:30 – 12:00

Proffered Paper Presentations

Proffered Paper Presentations

Proffered Paper Presentations

Proffered Paper Presentations

Proffered Paper Presentations

12:00 – 13:00

Lunch, Posters and Networking



**Presidential Session: Female Leaders and Innovators Forum; An Athena Swan Initiative**

**Chair: Mary Harney**

*Former Minister for Health and Deputy Prime Minister, Ireland*

**Francoise Meunier**

*Director of Special Projects, European Association for the Research and Treatment of Cancer, Brussels, Belgium, Vice-President, Federation of European Academies of Medicine, Brussels, Belgium*

**13:30 – 15:00**

**Karen Knudson**

*Director- NCI-Designated Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, USA*

**Irene Norstedt**

*Deputy Head of Personalised Medicine, DG Research and Innovation, European Commission (TBC)*

**Lillian Siu**

*Professor of Medicine, Princess Margaret Cancer Centre, University of Toronto, Canada*

**14:30 – 15:00**

**Coffee, Posters and Networking**

**Patient Advocacy Award**

**15:00 – 16:30**

**Parallel Sessions**

**Systems Medicine and Personalised Health**

**Personalised Medicine and Public Health: Two Sides of the Same Coin?**

**Fixing Cystic Fibrosis Transmembrane Conductance Regulator (CFTR): Targeting therapies which make a difference**

**Health Literacy: A Key Component of Personalised Health and Innovation**

**Genomics, DNA and Diaspora**

**Nuria Malats**  
*Group Leader, Genetic and Molecular Epidemiology Group, Spanish National Cancer Research Centre*

**Chair: Walter Ricciardi**  
*Instituto Superiore di Sanità Italy*

**Co-Chair: J Stuart Elborn**  
*Imperial College and Royal Brompton Hospital, London and Queen's University Belfast, UK*

**Co-Chair: Denis Horgan**  
*European Alliance for Personalised Medicine, Brussels, Belgium*

**Co-Chair: Eimear Kenny**  
*Assistant Professor, Icahn School of Medicine at Mount Sinai, NY, USA*

**Co-Chair: Lorraine Martin**  
*Professor of Molecular Pharmaceutics, School of Pharmacy, Queen's University Belfast, UK*

**Co-Chair: Joe McHugh TD**  
*Minister of State for the Diaspora and International Development (TBC)*

**Walter Kolch**  
*Director, Systems Biology Ireland, University College Dublin, Ireland (TBC)*

**Nina Renshaw**  
*Secretary General, European Public Health Alliance (TBC)*

**"How the Cystic Fibrosis Transmembrane Regulator (CFTR) works"**  
**Lorraine Martin**  
*Professor of Molecular Pharmaceutics, School of Pharmacy, Queen's University Belfast, UK*

**Holger Moch**  
*Medical Director and Chairman, Department of Pathology & Molecular Pathology, University Hospital Zurich, Switzerland*

**John Greally**  
*Professor, Faculty Scholar for Epigenetics, Albert Einstein College of Medicine, New York, USA*

**Dan Longley**  
*Chair of Cancer Biology, Queens University Belfast, UK*

**Paul De Raeve**  
*Secretary General, European Federation of Nurses (TBC)*

**"Modulating the Cystic Fibrosis Transmembrane Regulator (CFTR): How New Drugs were developed"**  
**Mark Higgins**  
*Vertex, Boston, US*

**Stephen McMahon**  
*Chairman and co-founder of the Irish Patients' Association (IPA) (TBC)*

**Dan Bradley**  
*Principal Investigator, molecular Population Genetics, Smurfit Institute of Genetics, Trinity College Dublin*

	<p><b>Jochen Prehn</b> <i>Director, Centre for Systems Medicine, Royal College of Surgeons in Ireland, Dublin, Ireland</i></p> <p><b>Speaker to be confirmed</b></p>	<p><b>Speaker to be confirmed</b></p>	<p><b>"Treating Cystic Fibrosis: New Clinical Trials."</b> <b>J Stuart Elborn</b> <i>Imperial College and Royal Brompton Hospital, London and Queen's University Belfast, UK</i></p>	<p><b>Kaisa Immonen</b> <i>Director of Policy, European Patient Forum</i></p>	<p><b>Eimear Kenny</b> <i>Assistant Professor, Icahn School of Medicine at Mount Sinai, NY, USA</i></p>
	<p><b>Speaker to be confirmed</b></p>	<p><b>Frank Kee</b> <i>Director, UKCRC Centre for Excellence for Public Health Research (NI), Queen's University Belfast, UK</i></p>	<p><b>"Living with Cystic Fibrosis"</b> <b>Michelle Francis Naylor</b> <i>Belfast, UK</i></p>	<p><b>Kristine Sørensen</b> <i>Founder, Global Health Literacy Academy, The Netherlands</i></p>	<p><b>Tõnu Esko</b> <i>Deputy Director of Research, Estonian Biobank, Estonian Genome Center, University of Tartu, Estonia (TBC)</i></p>
		<p><b>Kaisa Immonen</b> <i>Director of Policy, European Patient Forum</i></p>	<p><b>"Future Challenges, Policy and Science"</b> <b>Janet Allen</b> <i>Director of Strategic Innovation, Cystic Fibrosis Trust, Southampton, UK</i></p>	<p><b>Geoffrey Henning</b> <i>Policy Director, EuropaColon, Brussels, Belgium</i></p>	
				<p><b>Industry Speaker to be confirmed</b></p>	
16:30 – 17:00	Proffered Paper Presentations	Proffered Paper Presentations	Proffered Paper Presentations	Proffered Paper Presentations	Proffered Paper Presentations
17:00 – 17:30	Coffee, Posters and Networking				
	Speed Networking				
	Meet the Cancer Patient	Meet the Diabetes Patient	Meet the Patient (Brain Diseases)	Meet the Patient with co-morbidities	Meet the Rare Disease Patient
17:30 – 19:00	<p><b>Shooting for the Moon or Flying too near the Sun: Crossing the Value Rubicon in Precision Care</b></p> <p><b>Co-Chair: Mark Lawler</b> <i>Chair in Translational Cancer Genomics, Queen's University Belfast, UK</i></p> <p><b>Co-Chair: Richard Sullivan</b> <i>Director, Institute of Cancer Policy, King's College London UK</i></p> <p><b>Richard Sullivan</b> <i>Director, Institute of Cancer Policy, King's College London UK</i></p> <p><b>Tito Fojo</b> <i>Professor of Medicine, Columbia University, New York, USA</i></p> <p><b>Mark Lawler</b> <i>Chair in Translational Cancer Genomics, Queen's University Belfast, UK</i></p> <p><b>Virginia Acha</b> <i>Executive Director, Research, Medical and Innovation, Association of the British Pharmaceutical Industry (ABPI), UK</i></p>				
19:00 – 20:00	Poster Session				
20.00 - late	Whiskey tasting and Special Performance				

# 30 November 2017

07:30 – 08:30	Highlights of the Day and Press Briefing				
07:00 – 08:00	Meet the Professor	Meet the Professor/ Business Leader	Meet the Policy Maker	Meet the Patient Advocate	Meet the Professor/ Business Leader
08:00 – 09:30	<p><b>Presidential Session: Public-private partnership and personalised medicine</b></p> <p><b>Chair: Pierre Meulien</b> <i>Innovation Medicines Initiative (IMI)</i></p> <p><b>Kaja Kallas</b> <i>Member of the European Parliament (TBC)</i></p> <p><b>Kathy Oliver</b> <i>International Brain Tumor Alliance (IBTA)</i></p> <p><b>Speakers to be confirmed</b></p>				
09:30 – 10:00	Coffee, Posters and Networking				
10:00 – 11:30	Parallel Sessions				
	<p><b>The Challenges of Precision Oncology Drug Development and Implementation</b></p>	<p><b>Connected Health – Defining the Vision and Business in a Changing Environment</b></p>	<p><b>We are what we eat – preserving health through enhanced nutrition</b></p>	<p><b>Precision Pathology in LMICs - unaffordable luxury or relevant necessity?</b></p>	<p><b>CCRCB – ALMAC Session – The Realities of Delivering Personalised Medicine in Clinical Trials</b></p>
<p><b>Co-Chair: Andrew Biankin</b> <i>Regius Chair of Surgery/Director of Translational Research Centre, University of Glasgow</i></p>	<p><b>Brian O'Connor</b> <i>Chair, European Connected Health Alliance</i></p>	<p><b>Chair: Christopher Elliott</b>, <i>Chair of Food Safety &amp; Microbiology, Pro Vice Chancellor Faculty of Medicine, Health and Life Sciences, Queen's University Belfast, UK</i></p>	<p><b>Co-Chair: Kathy Oliver</b> <i>Founding Co-Director, International Brain Tumour Alliance (IBTA) (TBC)</i></p>	<p><b>Chair: Richard Kennedy</b> <i>McClay Professor in Medical Oncology, Queen's University Belfast, UK</i></p>	
<p><b>Co-Chair: Simon Hollingsworth</b> <i>Executive Director Oncology; Global Project Director, AstraZeneca, Cambridge, UK</i></p>			<p><b>Co-Chair: Kenneth Fleming</b> <i>Senior Advisor for Pathology, Centre for Global Health NCI, Washington</i></p>		
<p><b>“Challenges of Contemporary Therapeutic Development”</b> <b>Simon Hollingsworth</b> <i>Executive Director Oncology; Global Project Director, AstraZeneca, Cambridge, UK</i></p>	<p><b>Speakers to be confirmed</b></p>	<p><b>Precision Nutritional Catering for the Vulnerable: Can this be achieved?”</b> <b>Moira Dean</b> <i>Institute for Global Food Security, Queen's University, Belfast</i></p>	<p><b>Kenneth Fleming</b> <i>Senior Advisor for Pathology, Centre for Global Health NCI, Washington</i></p>	<p><b>Ken Emancipator</b> <i>Executive Medical Director, Merck, New York, USA</i></p>	
<p><b>“Diversity and Defining Actionability of Molecular Events”</b> <b>Philip Beer</b> <i>Precision oncology, cancer genomics and next-generation therapeutics - Cure Forward Corp., Cambridge, UK</i></p>		<p><b>“Delivering a breakthrough in human nutrition and health through delivery of omega oils in chicken meat”</b> <b>Alice Stanton</b> <i>Royal College of Surgeons in Ireland, Dublin, Ireland</i></p>	<p><b>Richard Sullivan</b> <i>Director, Institute of Cancer Policy, King's College London UK</i></p>	<p><b>Darren Hodgson</b> <i>Senior Principal Translational Scientist, AstraZeneca, Stockport, UK</i></p>	

<p><b>“Finding patients for trials/Finding Trials for Patients”</b>  <b>IBM Watson Speaker</b>  <i>(TBC)</i></p> <p><b>“Effective Strategies for approval and adoption”</b> <b>Robert Hemmings</b>  <b>Krishna Prasad</b>  <i>MHRA (TBC)</i></p> <p><b>“Composite Datasets and Knowledge Banks”</b>  <b>Andrew Biankin</b>  <i>Regius Chair of Surgery/Director of Translational Research Centre, University of Glasgow, UK</i></p>		<p><b>Speakers to be confirmed</b></p>	<p><b>Mark Lawler</b>  <i>Chair in Translational Cancer Genomics, Queen's University Belfast, UK</i></p> <p><b>Sue Horton</b>  <i>Professor and GICI Chair in Global Health Economics, University of Waterloo, Canada (TBC)</i></p> <p><b>Round Table Discussion</b></p>	<p><b>Matt Squires</b>  <i>Executive Director Oncology Precision Medicine Novartis, Basel, Switzerland</i></p>
---	--	--	--	--

11:30 – 12:00	Proffered Paper Presentations?	Proffered Paper Presentations?	Proffered Paper Presentations?	Proffered Paper Presentations?	Proffered Paper Presentations?
---------------	--------------------------------	--------------------------------	--------------------------------	--------------------------------	--------------------------------

12:00 – 13:00	<b>Lunch, Posters and Networking</b>				
---------------	--------------------------------------	--	--	--	--

13:00 – 14:30	<p><b>Presidential Session: Regulating the future - Balance of patient safety and facilitating Innovation (EMA - FDA)</b></p> <p><b>Chair: Denis Horgan</b>  <i>Executive Director, European Alliance for Personalised Medicine</i></p> <p><b>Juergen Scheuenpflug</b>  <i>Global Head Clinical Biomarkers &amp; Companion Diagnostics, Merck</i></p> <p><b>Urve Palo</b>  <i>Minister of Entrepreneurship and Information Technology, Estonia (TBC)</i></p> <p><b>Iñaki Gutiérrez-Ibarluzea</b>  <i>Vice President en Health Technology Assessment international (HTAi), Basque Region Spain</i></p> <p><b>Francesco De Lorenzo</b>  <i>President, European Cancer Patient Coalition, Brussels, Belgium</i></p> <p><b>HPRA Speaker</b>  <i>Dublin, Ireland (TBC)</i></p> <p><b>Greg Kalbaugh</b>  <i>Executive Director, Global Government Affairs, Alexion Pharmaceuticals, Inc.</i></p>				
---------------	--	--	--	--	--

14:30 – 15:00	<b>Coffee, Posters and Networking</b>				
---------------	---------------------------------------	--	--	--	--

	<b>Speed Networking</b>				
	Meet the Cancer Patient	Meet the Diabetes Patients	Meet the Patient (Brain Diseases)	Meet the Patient with co-morbidities	Meet the Rare Disease Patient

<p><b>EAU Special Session</b>  <b>Every Prostate cancer is unique: Personalised prostate cancer diagnosis and management</b></p>	<p><b>Discovery Network: a new approach to driving research</b></p>	<p><b>Diabetes: A Personalised Health Epidemic</b></p>	<p><b>Molecular Diagnostics – Enabling the Personalised Medicine Revolution</b></p>	<p><b>HTA, Payers &amp; the European Medicines Agency – Crossing the Rubicon</b></p>
<p><b>Chair: Hendrik Van Poppel</b>  <i>European Association of Urology</i></p>	<p><b>Chair: Peter Kapitein</b>  <i>Inspire2Live, The Netherlands</i></p>	<p><b>Chair: Olivier Arnaud</b>  <i>Senior Director, Juvenile Diabetes Research Foundation</i></p>	<p><b>Co-Chair: David Barton</b>  <i>National Centre for Medical Genetics Crumlin</i></p>	<p><b>Co-Chair: Lou Garrison</b>  <i>University of Washington, USA</i></p>
<p><b>Nicolas Mottet</b>  <i>Urology Department Head at CHU St Etienne - Université Jean Monnet, St Etienne, France</i></p>	<p><b>Stephen Friend</b>  <i>Chariman, Co-Founder and Past President Sage Bionetworks; Leader Health Team, Apple Inc.</i></p>	<p><b>"Pediatric vs Adult onset Type 1 Diabetes – Clinical Considerations in Therapy Development"</b>  <b>Colin Dayan</b>  <i>Professor of Clinical Diabetes and Metabolism Cardiff University, UK</i></p>	<p><b>Co-Chair: Mario Pazzagli</b>  <i>University of Florence, Italy</i></p>	<p><b>Co-Chair: Denis Horgan</b>  <i>European Alliance for Personalised Medicine, Brussels, Belgium</i></p>
<p><b>Rodolfo Montironi</b>  <i>President, International Society of Urological Pathology, Ancona, Italy</i></p>	<p><b>Mark Lawler</b>  <i>Chair in Translational Cancer Genomics, Queen's University Belfast, UK</i></p>	<p><b>"Staging Type 1 Diabetes and its Prevention through Innovative Interventions"</b>  <b>Ake Lernmark</b>  <i>M.D., LU Diabetes Centre, Lund University, Sweden</i></p>	<p><b>"The new IVD regulation"</b>  <b>David Barton</b>  <i>Chief Scientist, National Centre for Medical Genetics Crumlin</i></p>	<p><b>Clare Hague</b>  <i>Director of Health Economics &amp; Outcomes research Medical Affairs, Celgene</i></p>
<p><b>Thorsten Bach</b>  <i>Chairman EAU Patient Information Projekt, European Association of Urology</i></p>	<p><b>Speakers to be confirmed</b></p>	<p><b>"Realizing the Potential of Novel Interventions in Type 1 Diabetes"</b>  <b>Thomas Danne</b>  <i>M.D., Diabetes Centre for Children and Adolescents, Hannover, Germany</i></p>	<p><b>"A Workflow for molecular diagnostics in clinical oncology"</b>  <b>Mario Pazzagli</b>  <i>Professor of Clinical Biochemistry, Department of Clinical and Experimental Biochemical Science University of Florence, Italy (TBC)</i></p>	<p><b>Carole Longson</b>  <i>Director, Centre for Health Technology Evaluation and Executive Director, National Institute for Health Care &amp; Excellence (NICE), London, UK</i></p>
<p><b>Thorsten Bach</b>  <i>Chairman EAU Patient Information Projekt, European Association of Urology</i></p>	<p><b>Speakers to be confirmed</b></p>	<p><b>"Flushing out the truth! Development of a multiplex urinary tract infection detection test"</b>  <b>Martin Crockard</b>  <i>Molecular Diagnostics Manager, Randox Laboratories Ltd, Antrim, UK</i></p>	<p><b>"Flushing out the truth! Development of a multiplex urinary tract infection detection test"</b>  <b>Martin Crockard</b>  <i>Molecular Diagnostics Manager, Randox Laboratories Ltd, Antrim, UK</i></p>	<p><b>Hans-Georg Eichler</b>  <i>MD, MSc, Senior Medical Officer, European Medicines Agency (EMA), London, UK</i></p>



**Ian Banks**  
*President, European Men's Health Forum*

**Robert Jan Smits**  
*Director-General of DG Research and Innovation - European Commission (TBC)*

**"Benchmarking the quality of next generation sequencing in Clinical Oncology"**  
**Simon Patton**  
*Director at European Molecular Genetics Quality Network (EMQN) - European Molecular Genetics Quality Network (EMQN) (TBC)*

**Lars Pedersen**  
*MSc, PhD, Professor, Department of Clinical Epidemiology, Aarhus University, Aarhus, Denmark (TBC)*

**Rob Vries**  
*Hubrecht institute / The HUB foundation for Organoid Technology, Hubrecht, The Netherlands*

**Casper Van Eijck**  
*Surgeon at Erasmus MC - Rotterdam, The Netherlands*

**Closing of conference: Keeping the promise and preparing for the future**

**Jevgeni Ossinovski**  
*Minister of Health, Estonia*

**David Byrne**  
*Chair European Alliance for Personalised Medicine, Brussels, Belgium*

**Speaker to be confirmed**

**Stephen Friend**  
*Chairman, Co-Founder and Past President Sage Bionetworks; Leader Health Team, Apple Inc.*

**Stanimir Hasurdjiev**  
*Secretary-General of the Patient Access Partnership*

16:30 - 17:30

**Next Steps to Realise the Congress Conclusions**

**Denis Horgan**  
*EAPM Executive Director*

**Mark Lawler**  
*Chair in Translational Cancer Genomics, Queen's University Belfast, UK*

17:30 - 17:45

